News | July 13, 2022
Eversana partners with Compai Pharma to expand commercialisation services across APAC
EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners
EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners
We must try to make the health care system more accessible for people with disabilities
It´s the first trial to demonstrate the benefits of dual pathway inhibition
Dr. Bernstein will tap into her decades of leadership and strategy experience as she transitions into this new role at APhA
The European Commission granted CMA in December 2021 for use of Nuvaxovid in individuals aged 18 and over, and Novavax filed for expanded CMA for use in adolescents aged 12 through 17 in March 2022
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
A comprehensive assessment of the organisational systems for governance, management, operations and consistency in delivered results, this certification is an endorsement of the company's export capabilities and manufacturing prowess
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
This targeted capacity-building and advocacy project in 15 districts and 5 states of India has facilitated the certification of disability for 11,152 people, provided disability pensions to 8,144 people and supported the issuing of voter IDs to 8,450 people with disabilities
Subscribe To Our Newsletter & Stay Updated
